LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01125566|
Recruitment Status : Completed
First Posted : May 18, 2010
Results First Posted : August 21, 2014
Last Update Posted : July 18, 2019
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Breast Neoplasms||Drug: BIBW 2992 Drug: trastuzumab Drug: vinorelbine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||508 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment|
|Actual Study Start Date :||June 22, 2010|
|Actual Primary Completion Date :||June 8, 2013|
|Actual Study Completion Date :||July 6, 2018|
Active Comparator: Arm B: trastuzumab with vinorelbine
patients receive weekly intravenous infusion of trastuzumab and vinorelbine
patients receive trastuzumab 2mg/kg intravenously every week
patients receive vinorelbine 25mg/m² intravenously every week
Experimental: Arm A: BIBW 2992 with vinorelbine
patients receive BIBW 2992 tablets once daily combined with weekly intravenous infusion of vinorelbine
Drug: BIBW 2992
patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
patients receive vinorelbine 25mg/m² intravenously every week
- Progression-free Survival (PFS) [ Time Frame: From randomization (07Sep2010) until disease progression, death or data cut-off (08Jun2013); Up to 34 months ]
PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by investigator according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). RECIST is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize") or worsen ("progress") during treatment.
Only data collected until the cut-off date for RECIST 1.1 based endpoints (08Jun2013) were considered.
Progression of disease was determined if at least 1 of the following criteria applied:
- At least a 20% increase in the sum of the diameters (SoD) of target lesions taking as reference the smallest SoD recorded since the treatment started, together with an absolute increase in the SoD of at least 5 mm
- Appearance of 1 or more new lesions
- Unequivocal progression of existing non-target lesions
- Overall Survival (OS) [ Time Frame: From randomisation (07Sep2010) to database lock (30Jul2018), up to 95 months. ]
OS is defined as time from randomisation to death irrespective of the cause of the death.
For patients who had not died up to the cut-off date (03Sep2013), the date they were last known to be alive was derived from the patient status records, the trial completion record, radiological imaging assessments, the study treatment termination record, and the randomisation date.
- Best RECIST Assessment [ Time Frame: From randomization (07Sep2010) until disease progression, death or data cut-off (08Jun2013); Up to 34 months ]
Best RECIST assessment is defined as CR, PR, stable disease (SD), progressive disease (PD) or not evaluable by investigator (RECIST version 1.1).
CR for target lesions (TL): Disappearance of all target lesions.
CR for non-target lesions (NTL): Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (<10mm short axis).
PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters.
SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as references the smallest SoD while on study.
PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions.
- Objective Response (OR) [ Time Frame: Post baseline tumour-imaging was performed at Week 8, 16, 24, 32, 40, 48, 56 and then every 12 weeks (Until final data-base lock on 30 Jul 2018; Up to 95 months) ]
OR is defined as complete response (CR) and partial response (PR). Assessed by investigator according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. Complete Response (CR) for target lesions (TL): Disappearance of all target lesions.
Complete Response (CR) for non-target lesions (NTL): Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (<10mm short axis)
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
Other factors which add to the overall response of an imaging timepoint as PR are as below:-
- CR in TL, but non-CR/Non-PD in NTL leads to PR
- CR in TL, but not evaluated NTL leads to PR
- PR in TL, but non-PD NTL or not all evaluated NTL leads to PR
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- Histologically confirmed diagnosis of HER2-overexpression breast cancer
- Stage IV metastatic disease
- Must have progressed on one prior trastuzumab treatment
- no more than one prior trastuzumab based therapy regimen (either adjuvant or first-line)
- Must have received anthracycline and/or taxane based chemotherapy for adjuvant treatment of breast cancer or first-line treatment of metastatic breast cancer
- Must have (archived) tumour tissue sample available for central re-assessment of HER2-status
- At least one measurable lesion according to RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 .
- Prior treatment with Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor(EGFR/HER2)-targeted small molecules or antibodies other than trastuzumab
- Prior treatment with vinorelbine
- Known pre-existing interstitial lung disease
- Active brain metastases
- History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomisation.
- Cardiac left ventricular function with resting ejection fraction of less than 50%.
- Patients unable to comply with the protocol.
- Any contraindications for therapy with vinorelbine or trastuzumab.
- Known hypersensitivity to BIBW 2992 or the excipients of any of the trial drugs.
- Use of any investigational drug within 4 weeks of randomisation.
- Inadequate hepatic, renal and haematologic organ function
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01125566
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Boehringer Ingelheim|
|Other Study ID Numbers:||
2009-015476-98 ( EudraCT Number )
|First Posted:||May 18, 2010 Key Record Dates|
|Results First Posted:||August 21, 2014|
|Last Update Posted:||July 18, 2019|
|Last Verified:||July 2019|
Neoplasms by Site
Antineoplastic Agents, Immunological
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors